SERS Detection of the Anti-Epileptic Drug Perampanel in Human Saliva.
Anti-Epileptic Drug (AED)
Perampanel
Surface Enhanced Raman Scattering (SERS)
Therapeutic Drug Monitoring (TDM)
human saliva
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
24 May 2023
24 May 2023
Historique:
received:
20
04
2023
revised:
15
05
2023
accepted:
19
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Surface-Enhanced Raman Scattering (SERS) can obtain the spectroscopic response of specific analytes. In controlled conditions, it is a powerful quantitative technique. However, often the sample and its SERS spectrum are complex. Pharmaceutical compounds in human biofluids with strong interfering signals from proteins and other biomolecules are a typical example. Among the techniques for drug dosage, SERS was reported to detect low drug concentrations, with analytical capability comparable to that of the assessed High-Performance Liquid Chromatography. Here, for the first time, we report the use of SERS for Therapeutic Drug Monitoring of the Anti-Epileptic Drug Perampanel (PER) in human saliva. We used inert substrates decorated with gold NPs deposited via Pulsed Laser Deposition as SERS sensors. We show that it is possible to detect PER in saliva via SERS after an optimized treatment of the saliva sample. Using a phase separation process, it is possible to extract all the diluted PER in saliva from the saliva phase to a chloroform phase. This allows us to detect PER in the saliva at initial concentrations of the order of 10
Identifiants
pubmed: 37298786
pii: molecules28114309
doi: 10.3390/molecules28114309
pmc: PMC10254353
pii:
doi:
Substances chimiques
perampanel
H821664NPK
Pyridones
0
Gold
7440-57-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Molecules. 2021 Dec 22;27(1):
pubmed: 35011263
Analyst. 2010 Mar;135(3):512-7
pubmed: 20174703
Epilepsia. 2013 Aug;54(8):1490-7
pubmed: 23772853
Biosensors (Basel). 2019 Apr 17;9(2):
pubmed: 30999661
Eur J Pharm Biopharm. 2015 Apr;91:16-24
pubmed: 25603197
J Contemp Dent Pract. 2006 May 01;7(2):104-11
pubmed: 16685301
Ther Drug Monit. 2013 Feb;35(1):4-29
pubmed: 23288091
Phys Chem Chem Phys. 2020 Nov 7;22(41):24070-24076
pubmed: 33079093
Angew Chem Int Ed Engl. 2019 Nov 11;58(46):16523-16527
pubmed: 31487420
Anal Chem. 2002 Jul 1;74(13):3160-7
pubmed: 12141678
Theranostics. 2022 Aug 8;12(13):5914-5930
pubmed: 35966585
Clin Chim Acta. 2014 Sep 25;436:224-36
pubmed: 24925169
Analyst. 2019 Nov 21;144(22):6698-6705
pubmed: 31599884
Biosensors (Basel). 2016 Sep 19;6(3):
pubmed: 27657146
Chem Rev. 2016 Dec 28;116(24):14921-14981
pubmed: 27739670
Curr Pharm Des. 2022;28(18):1445-1456
pubmed: 35593344
Clin Pharmacokinet. 1978 Jan-Feb;3(1):39-57
pubmed: 25155
Korean J Intern Med. 2009 Mar;24(1):1-10
pubmed: 19270474
Adv Mater. 2018 Feb;30(5):
pubmed: 29226594
Nanomaterials (Basel). 2019 May 01;9(5):
pubmed: 31052433
Epilepsia. 2020 Jun;61(6):1120-1128
pubmed: 32378757
Anal Chem. 2019 Feb 5;91(3):2100-2111
pubmed: 30580508
ACS Appl Mater Interfaces. 2022 Jan 26;14(3):4714-4724
pubmed: 35081679
J Pharm Anal. 2021 Aug;11(4):405-421
pubmed: 34513117
Seizure. 2015 Jul;29:46-62
pubmed: 26076844
Crit Rev Oral Biol Med. 2002;13(2):197-212
pubmed: 12097361